Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide.
about
Pharmacological Therapy in the Heart as an Alternative to Cellular Therapy: A Place for the Brain Natriuretic Peptide?Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic EventsHighlights of the year in JACC 2012Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chancesAngiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyondChronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure.BNP and Heart Failure: Preclinical and Clinical Trial Data.Innovative Therapeutics: Designer Natriuretic Peptides.Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications.BNP molecular forms and processing by the cardiac serine protease corin.Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects.Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.Molecular Screen Identifies Cardiac Myosin-Binding Protein-C as a Protein Kinase G-Iα Substrate.The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population.Timing and duration of interventions in clinical trials for patients with hospitalized heart failure.Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair.Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.The heart as an endocrine organ.Novel vasodilators in heart failure.Chemical methods for peptide and protein production.Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.Natriuretic peptides in cardiovascular diseases: current use and perspectivesNovel drug targets in clinical development for heart failure.cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.Mechanisms of renal hyporesponsiveness to BNP in heart failure.Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.B-type natriuretic peptide and heart failure: what can we learn from clinical trials?Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide.Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.Divergent effects of a designer natriuretic peptide CD-NP in the regulation of adipose tissue and metabolismChanges in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide.A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure.Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.Brain natriuretic peptide is able to stimulate cardiac progenitor cell proliferation and differentiation in murine hearts after birth.Post-transcriptional modification of pro-BNP in heart failure: is glycosylation and circulating furin key for cardiovascular homeostasis?The Janus face of BNP therapy in chronic heart failure: beneficial effects unmasked by β blockers?Natriuretic peptides and volume handling in heart failure: the paradigm of a new treatment.
P2860
Q26765883-F7A8DC6D-A6B9-4B82-B391-01CA825EA534Q26778333-3C0E0CA0-FE4C-4AA5-8BCD-5AAB8CFA166DQ26865608-2070CD28-1BB9-4375-829C-3A233D967ABBQ27027707-33DAF406-BF21-46A7-B205-3DC293312E5EQ28088583-3BCF5B44-3F41-4F19-A65E-99BE2433E56AQ30359729-F73A4A98-4F93-4925-8B7D-FDCBE90969FBQ30909922-CD302B94-ED3A-4CE5-B5E4-3BD9C49371ECQ33653332-292553D8-E9D4-4904-9C37-30E88F1ED50AQ34150487-C3208CEB-7EFB-4DDF-9D8E-EFEDC65D995EQ34369603-E02BFC89-FC2A-4914-8590-83AFD43991F3Q34421211-8AEF4917-4AEF-4BE0-B28D-3FB6A7EF215EQ34714245-8BA940E9-F1C1-4DCF-8C09-4EA6D235C46CQ36296869-CD8D6980-1E47-4F44-9748-31D892AEBF39Q37106593-727F1C75-AEF9-4044-AB39-C2832492008AQ37354429-4979BEFE-5C75-4224-B7C5-5939187CC1EAQ37405644-FD83EACB-4242-4B67-A6D4-E86B536A1951Q37694008-58B18575-CACB-4B40-A63E-0AD5406D986BQ37703738-DBA98B5A-745C-4FF7-8C23-6C2DD5536BADQ38072635-5D96429A-7EAE-4B50-938A-4DB5F5105E84Q38098836-8F427190-A294-462B-99B6-6D55B853E5FDQ38110226-2E1A085D-5E0F-4402-841B-B2F56176428AQ38162429-DC958C74-5F26-464A-A47E-B6D51286BA2FQ38202895-4A140E31-013D-45FF-A888-B0BF91BE777DQ38220091-AB21D9AE-8FB8-4DA9-8E23-16F10B65362FQ38261513-28447525-6B6B-497C-A7AF-CBBBCD68C7F1Q38424318-C17609E4-58AE-4E0D-A3EE-18A09403B1F3Q38790076-9E83A7EC-88CB-4DE9-9B89-2044CF8ABDE2Q38987185-326DFFD8-5949-42C6-8CCA-EDDC1777A092Q39007435-F2C50091-C205-4AC1-9821-48712D193E7FQ39159036-4CFB5083-420B-47A1-AA58-CB52B3FA2EFEQ40000430-B1425034-A8F3-4C7B-9DE8-581026C54C1CQ42010491-754E9ECD-6FD1-4F98-86D4-87FB0A7C2908Q42880557-2C3516B2-A0D0-4D99-965F-A18DD92E213EQ47789951-70374B75-5248-401F-9E19-FD59ED18EB4BQ47855200-5E437EC8-E011-4B95-AF43-AAB8C45DD1F4Q48435084-43215B4F-BB05-42A0-B387-27FD0027F064Q48524333-12A1E9AE-2CE7-494D-8C17-FFEF971B4D38Q48700962-94B4BA44-41EF-47F8-89B9-3960DAE9A988Q48722122-7D640950-FC24-45F8-A6AF-F54D32FEDF84
P2860
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Novel protein therapeutics for ...... us B-type natriuretic peptide.
@ast
Novel protein therapeutics for ...... us B-type natriuretic peptide.
@en
type
label
Novel protein therapeutics for ...... us B-type natriuretic peptide.
@ast
Novel protein therapeutics for ...... us B-type natriuretic peptide.
@en
prefLabel
Novel protein therapeutics for ...... us B-type natriuretic peptide.
@ast
Novel protein therapeutics for ...... us B-type natriuretic peptide.
@en
P2093
P2860
P1476
Novel protein therapeutics for ...... us B-type natriuretic peptide.
@en
P2093
Alessandro Cataliotti
Horng H Chen
James F Glockner
John A Schirger
John C Burnett
Margaret M Redfield
P2860
P304
P356
10.1016/J.JACC.2012.07.056
P407
P577
2012-11-01T00:00:00Z